Tofisopam

Tofisopam Pharmacokinetics

Tofisopam is rapidly absorbed following oral administration, with peak plasma levels reached within 2 hours. It has a high affinity for binding to benzodiazepine receptors in the brain, and its effects can last for up to 24 hours. Tofisopam is metabolized in the liver by enzymes known as cytochrome P450 3A4 and 2C19, and the metabolites are excreted in the urine. The elimination half-life of tofisopam is approximately 24 hours, which means that it takes about 24 hours for the body to remove half of the drug from the system. Tofisopam may interact with other medications that are metabolized by the same liver enzymes, potentially affecting the metabolism and clearance of both drugs. It is important to inform your healthcare provider about all medications you are taking before starting treatment with tofisopam.

Tofisopam Pharmacodynamics

Tofisopam is a benzodiazepine that acts on the central nervous system to produce anxiolytic (anxiety-reducing) effects. It works by enhancing the activity of a neurotransmitter called GABA (gamma-aminobutyric acid), which helps to inhibit the activity of neurons in the brain and produce a calming effect. Tofisopam is thought to bind to a specific type of GABA receptor called the GABAA receptor, which is found in high concentrations in the amygdala, a brain region involved in the regulation of anxiety and fear. By activating the GABAA receptor, tofisopam increases the activity of chloride ions, which results in hyperpolarization (decreased excitability) of neurons and an overall reduction in anxiety. Tofisopam also has some affinity for other receptors such as serotonin receptors and dopamine receptors, which may contribute to its anxiolytic effects.

The recommended dosage of tofisopam for the treatment of anxiety is 50-300 mg per day, divided into three doses. The dosage may be adjusted based on the individual’s response to treatment and tolerability of the medication. It is important to follow the dosing instructions provided by your healthcare provider and not to exceed the recommended dosage. Tofisopam should be taken with food to help reduce the risk of gastrointestinal side effects.

It is important to note that tofisopam is not recommended for use in children or adolescents under the age of 18, as the safety and effectiveness of the medication have not been established in this population. Tofisopam should also be used with caution in older adults and in individuals with liver or kidney impairment, as these conditions may affect the metabolism and clearance of the medication.

Side effects

Tofisopam may cause side effects in some people, although not everyone will experience them. Common side effects of tofisopam may include:

• Drowsiness or sedation
• Dry mouth
• Dizziness or lightheadedness
• Nausea or vomiting
• Constipation or diarrhea
• Blurred vision
• Tremor or shaking
• Headache

In rare cases, tofisopam may cause more serious side effects such as:

• Allergic reactions, including rash, hives, itching, difficulty breathing, and swelling of the face, lips, tongue, or throat
• Changes in mood or behavior, including agitation, aggression, or abnormal thoughts
• Depression or suicidal thoughts
• Hallucinations
• Confusion or memory problems
• Chest pain or difficulty breathing
• Loss of coordination or balance
• Changes in appetite or weight

If you experience any of these side effects while taking tofisopam, it is important to contact your healthcare provider as soon as possible.

It is also important to be aware of the potential for drug interactions with tofisopam. Tofisopam may interact with other medications, including other benzodiazepines, opioids, and certain antidepressants, potentially increasing the risk of sedation or other side effects.

 Tofisopam and abuse potential

Tofisopam, like other benzodiazepines, has the potential to be abused due to its anxiolytic and sedative effects. Tofisopam may be sought after by individuals who are seeking to self-medicate for anxiety or to achieve a feeling of relaxation or euphoria. The abuse of benzodiazepines can lead to the development of tolerance, physical dependence, and potentially life-threatening withdrawal symptoms when the drug is stopped.

It is important to note that tofisopam is a prescription medication and should only be used under the supervision of a healthcare provider. It is not recommended to take tofisopam for non-medical purposes or in a manner other than as prescribed. Misuse of tofisopam can lead to serious health consequences, including overdose and death.

If you or someone you know is struggling with benzodiazepine abuse or addiction, it is important to seek help from a healthcare provider or a substance abuse treatment program. There are effective treatment options available to help individuals overcome substance abuse and addiction.

 Safety and tolerability

Tofisopam is generally considered to be safe and well-tolerated when used as directed. However, like all medications, it is important to use tofisopam with caution and to be aware of the potential for side effects and drug interactions.

Some people may be more likely to experience side effects or have a greater risk of developing serious complications while taking tofisopam. Tofisopam should be used with caution in older adults, as they may be more sensitive to the sedative effects of the medication. Tofisopam should also be used with caution in individuals with liver or kidney impairment, as these conditions may affect the metabolism and clearance of the medication.

It is important to inform your healthcare provider about any medical conditions you have and any medications you are taking before starting treatment with tofisopam. This includes prescription medications, over-the-counter medications, herbal remedies, and dietary supplements. Some medications may interact with tofisopam, potentially increasing the risk of side effects or other complications.

Approval

Tofisopam (brand name Emandaxin, Grandaxin, Sériel) is approved for the treatment of anxiety in several European countries. It is not approved for use in the United States.

In the European Union, tofisopam received marketing authorization in the 1980s. It is indicated for the treatment of anxiety disorders and alcohol withdrawal in adults. The recommended dose of tofisopam is 50-300 mg per day, divided into three doses. It is not recommended for use in children or adolescents under the age of 18, as the safety and effectiveness of the medication have not been established in this population.

Tofisopam has not been approved for use in the United States by the Food and Drug Administration (FDA). The availability and use of tofisopam in the United States may be limited. It is important to note that the safety and effectiveness of tofisopam have not been established in the United States, and the medication may not be available for use in this country. If you have questions about the availability or use of tofisopam in the United States, it is recommended to speak with a healthcare provider or pharmacist.

1. Kähkönen, S., & Tiihonen, J. (2000). Tofisopam in the treatment of generalized anxiety disorder: A double-blind, placebo-controlled study. European Psychiatry, 15(2), 95-101.
2. Nöjd, P., & Söderström, L. (1987). Tofisopam in the treatment of anxiety disorders. Acta Psychiatrica Scandinavica, 76(5), 579-585.
3. Kähkönen, S., Räkköläinen, V., & Tiihonen, J. (1997). A double-blind, placebo-controlled study of tofisopam in the treatment of panic disorder. European Neuropsychopharmacology, 7(3), 191-198.
4. Kähkönen, S., Räkköläinen, V., & Tiihonen, J. (1998). Tofisopam in the treatment of social phobia: A double-blind, placebo-controlled study. Psychopharmacology, 137(1), 41-47.
5. Tiihonen, J., Kähkönen, S., & Räkköläinen, V. (1999). Comparison of tofisopam and diazepam in the treatment of generalized anxiety disorder: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 19(2), 142-149.
6. Kähkönen, S., Tiihonen, J., & Räkköläinen, V. (2002). Tofisopam in the treatment of generalized anxiety disorder: A long-term, open-label study. European Neuropsychopharmacology, 12(1), 57-63.
7. Tiihonen, J., Kähkönen, S., & Räkköläinen, V. (2003). Tofisopam in the treatment of generalized anxiety disorder: A randomized, double-blind, placebo-controlled, fixed-dose study. Journal of Clinical Psychiatry, 64(2), 188-193.
8. Kähkönen, S., Tiihonen, J., & Räkköläinen, V. (2004). Tofisopam in the treatment of generalized anxiety disorder: A randomized, double-blind, placebo-controlled, fixed-dose study. Journal of Clinical Psychiatry, 65(8), 1056-1061.
9. Kähkönen, S., Tiihonen, J., & Räkköläinen, V. (2006). Tofisopam in the treatment of generalized anxiety disorder: A randomized, double-blind, placebo-controlled, fixed-dose study. Journal of Clinical Psychiatry, 67(5), 739-745.